BSW
GYRE icon

Buckingham Strategic Wealth’s Gyre Therapeutics GYRE Stock Holding History

Buckingham Strategic Wealth’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,873
Closed -$22.7K – 707
2023
Q1 		$22.7K Sell
2,873
-2,874
-50% -$10.9K ﹤0.01% 611
2022
Q4 		$22.7K Buy
+5,747
New +$23.5K ﹤0.01% 613

Other funds holding GYRE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Buckingham Strategic Wealth's GYRE Position: Q2 2023 in Review

Buckingham Strategic Wealth sold out of Gyre Therapeutics (GYRE) in Q2 2023, closing a stake of 2,873 shares — an estimated $22.7K sold.

Buckingham Strategic Wealth first reported a position in GYRE in Q4 2022 and held it in 2 quarters. The position peaked at $22.7K in Q1 2023. 28 funds tracked by Wall St. Rank hold GYRE as of Q2 2023.

  • Buckingham Strategic Wealth reported no remaining Gyre Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Buckingham Strategic Wealth sold 2,873 Gyre Therapeutics shares in Q2 2023, an estimated $22.7K.
  • Buckingham Strategic Wealth first reported a position in Gyre Therapeutics in Q4 2022 and held it in 2 quarters.
  • Buckingham Strategic Wealth's Gyre Therapeutics position peaked at $22.7K in Q1 2023.
  • 28 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2023.

Based on Buckingham Strategic Wealth's 13F filing for Q2 2023, filed 11 Aug 2023.